Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Illumina announces new and expanded oncology partnerships » 14:10
01/11/21
01/11
14:10
01/11/21
14:10
ILMN

Illumina

$380.12 /

+0.65 (+0.17%)

, BMY

Bristol-Myers

$64.75 /

+2.25 (+3.60%)

, MYGN

Myriad Genetics

$25.13 /

+0.91 (+3.76%)

, MRK

Merck

$84.65 /

+1.64 (+1.98%)

, KURA

Kura Oncology

$38.50 /

-0.63 (-1.61%)

Illumina (ILMN) announces…

Illumina (ILMN) announces a portfolio of new and expanded oncology partnerships that it said "further the company's commitment to develop standardized, globally distributable tools for precision oncology." Speaking today at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco, California, Illumina CEO, Francis deSouza, announced a series of oncology partnerships that he said "aim to expand the reach of its powerhouse comprehensive genomic profiling family of products, TruSight Oncology." Expanding on a collaboration that began in 2018, Bristol Myers Squibb (BMY) will develop a microsatellite instability CDx, as well as develop a diagnostic based on the content of TruSight Oncology 500 ctDNA, Illumina's first liquid biopsy assay. Both program expansions are planned for global use by Bristol Myers Squibb's portfolio of cancer therapeutics. The company's partnership with Kura Oncology (KURA) is focused on building a CDx claim for HRAS mutations in Head and Neck Squamous Cell Carcinomas, Illumina said. As previously reported, Illumina is partnering with Myriad (MYGN), with time-limited exclusivity in certain markets, to develop and commercialize distributed kits for the assessment of HRD and for Myriad to expand its HRD service offerings, through a combination of TruSight Oncology content and Myriad's myChoice CDx test. Additionally, Illumina and Merck (MRK) are conducting a study focused on the expanded TruSight Oncology HRD offering, the company reported.

ShowHide Related Items >><<
MYGN Myriad Genetics
$25.13 /

+0.91 (+3.76%)

MRK Merck
$84.65 /

+1.64 (+1.98%)

KURA Kura Oncology
$38.50 /

-0.63 (-1.61%)

ILMN Illumina
$380.12 /

+0.65 (+0.17%)

BMY Bristol-Myers
$64.75 /

+2.25 (+3.60%)

ILMN Illumina
$380.12 /

+0.65 (+0.17%)

12/22/20
Fly Intel: Top five analyst upgrades
12/22/20 OTR Global
Illumina upgraded to Positive from Mixed at OTR Global
12/22/20 Piper Sandler
Illumina upgraded to Overweight from Neutral at Piper Sandler
12/17/20 BTIG
Illumina upgraded to Buy from Neutral at BTIG
BMY Bristol-Myers
$64.75 /

+2.25 (+3.60%)

12/15/20 Goldman Sachs
Bristol-Myers upgraded to Conviction Buy from Buy at Goldman Sachs
12/09/20 Mizuho
Pentwater seeks to replace Bristol-Myers Squibb CVR trustee, says Mizuho
11/30/20 Citi
Bristol-Myers price target raised to $77 from $73 at Citi
11/23/20 BofA
BofA upgrades Schrodinger to Buy after 'major' collaboration announcement
MYGN Myriad Genetics
$25.13 /

+0.91 (+3.76%)

11/10/20 Piper Sandler
Myriad Genetics price target raised to $18 from $14 at Piper Sandler
08/17/20 Piper Sandler
ACOG recommendation 'extremely' positive for Natera and Progenity, says Piper
06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
MRK Merck
$84.65 /

+1.64 (+1.98%)

01/06/21 Citi
Citi opens 'positive catalyst watch' on Merck
01/05/21 Citi
Citi boosts Merck target to $105, says may be most undervalued in pharma
12/22/20 Mizuho
Autolus, Arcus among top 2021 oncology picks at Mizuho
12/21/20 Alliance Global Partners
Alliance Global Partners keeps Buy on Sellas following data from trials
KURA Kura Oncology
$38.50 /

-0.63 (-1.61%)

12/07/20 Wedbush
Kura Oncology price target raised to $56 from $44 at Wedbush
12/07/20 Barclays
Kura Oncology price target raised to $47 from $40 at Barclays
12/07/20 H.C. Wainwright
Kura Oncology price target raised to $45 from $40 at H.C. Wainwright
12/02/20 Stifel
Kura Oncology initiated with a Buy at Stifel
MYGN Myriad Genetics
$25.13 /

+0.91 (+3.76%)

MRK Merck
$84.65 /

+1.64 (+1.98%)

KURA Kura Oncology
$38.50 /

-0.63 (-1.61%)

ILMN Illumina
$380.12 /

+0.65 (+0.17%)

BMY Bristol-Myers
$64.75 /

+2.25 (+3.60%)

  • 09
    Dec
  • 06
    May
MRK Merck
$84.65 /

+1.64 (+1.98%)

ILMN Illumina
$380.12 /

+0.65 (+0.17%)

BMY Bristol-Myers
$64.75 /

+2.25 (+3.60%)

MRK Merck
$84.65 /

+1.64 (+1.98%)

ILMN Illumina
$380.12 /

+0.65 (+0.17%)

BMY Bristol-Myers
$64.75 /

+2.25 (+3.60%)

MRK Merck
$84.65 /

+1.64 (+1.98%)

ILMN Illumina
$380.12 /

+0.65 (+0.17%)

BMY Bristol-Myers
$64.75 /

+2.25 (+3.60%)

Hot Stocks
Myriad Genetics announces strategic collaboration with Illumina in oncology » 14:06
01/11/21
01/11
14:06
01/11/21
14:06
MYGN

Myriad Genetics

$25.01 /

+0.79 (+3.26%)

, ILMN

Illumina

$380.00 /

+0.53 (+0.14%)

Myriad Genetics (MYGN)…

Myriad Genetics (MYGN) announced a strategic collaboration with Illumina (ILMN) for Illumina to create a kit-based version of the myChoice companion diagnostic test for international markets. Paul J. Diaz, president and CEO, Myriad Genetics, said: "Increasing access to our products and better serving patients and healthcare providers are critical components of our mission to improve outcomes and our transformation plan to drive growth. The agreement between Myriad and Illumina combines companion diagnostics and next-generation sequencing to advance comprehensive genomic profiling of tumor samples and drive improved outcomes in oncology. This collaboration reflects our increasing focus on partnering with high-caliber healthcare leaders like Illumina to bring innovative solutions to the oncology market."

ShowHide Related Items >><<
MYGN Myriad Genetics
$25.01 /

+0.79 (+3.26%)

ILMN Illumina
$380.00 /

+0.53 (+0.14%)

MYGN Myriad Genetics
$25.01 /

+0.79 (+3.26%)

11/10/20 Piper Sandler
Myriad Genetics price target raised to $18 from $14 at Piper Sandler
08/17/20 Piper Sandler
ACOG recommendation 'extremely' positive for Natera and Progenity, says Piper
06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
ILMN Illumina
$380.00 /

+0.53 (+0.14%)

12/22/20
Fly Intel: Top five analyst upgrades
12/22/20 OTR Global
Illumina upgraded to Positive from Mixed at OTR Global
12/22/20 Piper Sandler
Illumina upgraded to Overweight from Neutral at Piper Sandler
12/17/20 BTIG
Illumina upgraded to Buy from Neutral at BTIG
MYGN Myriad Genetics
$25.01 /

+0.79 (+3.26%)

ILMN Illumina
$380.00 /

+0.53 (+0.14%)

ILMN Illumina
$380.00 /

+0.53 (+0.14%)

ILMN Illumina
$380.00 /

+0.53 (+0.14%)

ILMN Illumina
$380.00 /

+0.53 (+0.14%)

Over a week ago
Hot Stocks
Myriad Genetics to pursue alternatives for autoimmune business » 16:11
01/05/21
01/05
16:11
01/05/21
16:11
MYGN

Myriad Genetics

$21.57 /

+1.64 (+8.23%)

Myriad Genetics announced…

Myriad Genetics announced the completion of its strategic business unit and products review. Myriad's Autoimmune business includes the Vectra assay, an advanced multi-protein biomarker blood test to help patients and healthcare providers gain an objective measure of rheumatoid arthritis, or RA, disease activity. The Vectra score is designed to reveal the effectiveness of a given RA treatment plan, predicting radiographic progression, and guiding personalized medical management decisions to improve outcomes. Prior to the coronavirus pandemic, revenue for Vectra consistently exceeded $40M per year. In November on its earnings call, Myriad Genetics announced that it is also pursuing strategic alternatives for two other businesses: Myriad RBM, which provides contract research services for the pharmaceutical industry, and Myriad Dermatology, which includes the myPath Melanoma diagnostic test. The restructuring of Myriad International operations will focus direct selling efforts on market opportunities in Germany, France, and Japan, where the company said there is increasing demand for companion diagnostic, hereditary cancer, and kit-based products. Remaining international markets will be served through alternative business models, including authorized distributor partnerships. This realignment is designed to reduce operating costs and support growth, leading to approximately $5M in incremental cost savings upon full implementation. Myriad recently announced that the German Federal Joint Committee successfully completed the method evaluation assessment for the EndoPredict breast cancer prognostic test and reached a "positive" reimbursement decision. The company also announced that it is in the process of licensing its myChoice CDx companion diagnostic test to leading pathology institutes in Germany and France. In addition, Myriad will focus on large Asian markets such as Japan, which now represent the largest segments of its international business. Myriad has seen significant increases in BRACAnalysis CDx test volume in Japan with total revenue increasing 200% year-over-year to $7.5M in the September 2020 quarter. Myriad also recently received Japanese regulatory approval for BRACAnalysis CDx as a companion diagnostic for the PARP inhibitor olaparib for use in pancreatic and prostate cancer. These approvals increase the total addressable market for Myriad's companion diagnostic tests in Japan to approximately 60,000 patients per year.

ShowHide Related Items >><<
MYGN Myriad Genetics
$21.57 /

+1.64 (+8.23%)

MYGN Myriad Genetics
$21.57 /

+1.64 (+8.23%)

11/10/20 Piper Sandler
Myriad Genetics price target raised to $18 from $14 at Piper Sandler
08/17/20 Piper Sandler
ACOG recommendation 'extremely' positive for Natera and Progenity, says Piper
06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
MYGN Myriad Genetics
$21.57 /

+1.64 (+8.23%)

Over a month ago
Hot Stocks
Myriad Genetics presents study on myRisk Hereditary Cancer, riskScore tests » 07:06
12/11/20
12/11
07:06
12/11/20
07:06
MYGN

Myriad Genetics

$19.70 /

+1.03 (+5.52%)

In a spotlight poster…

In a spotlight poster discussion at the 2020 San Antonio Breast Cancer Symposium, Myriad Genetics presented a new study that shows how its myRisk Hereditary Cancer and riskScore tests can better inform individualized clinical screening and prevention strategies for women at risk of developing breast cancer. The new Myriad study highlights how riskScore, a proprietary tool used to evaluate a woman's risk of developing breast cancer, can accurately provide breast cancer risk information into a personalized assessment model for women carrying a pathogenic variant in the ATM gene. Myriad's riskScore test combines data from 20 years of genome-wide association studies with a validated algorithm that uses personal and family history. riskScore is performed in conjunction with Myriad's myRisk Hereditary Cancer test, where myRisk identifies people who carry specific cancer-linked genetic mutations. Title: Development of a breast cancer risk assessment model for ATM mutation carriers incorporating Tyrer-Cuzick and a polygenic risk score: This study highlights the development of a comprehensive breast cancer risk model for ATM PV carriers incorporating an 86-variant PRS, along with family history and clinical information captured by Tyrer-Cuzick. The study found that with ATM PV carriers, a comprehensive model allowed for differentiation of carriers into low, moderate, and high breast cancer risk categories.

ShowHide Related Items >><<
MYGN Myriad Genetics
$19.70 /

+1.03 (+5.52%)

MYGN Myriad Genetics
$19.70 /

+1.03 (+5.52%)

11/10/20 Piper Sandler
Myriad Genetics price target raised to $18 from $14 at Piper Sandler
08/17/20 Piper Sandler
ACOG recommendation 'extremely' positive for Natera and Progenity, says Piper
06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
MYGN Myriad Genetics
$19.70 /

+1.03 (+5.52%)

Conference/Events
SABC / CTRC / AACR to co-host San Antonio Breast Cancer Virtual Symposium » 05:55
12/11/20
12/11
05:55
12/11/20
05:55
A

Agilent

$118.84 /

+2.285 (+1.96%)

, AMGN

Amgen

$228.17 /

-1.61 (-0.70%)

, ATNX

Athenex

$11.79 /

-0.31 (-2.56%)

, AZN

AstraZeneca

$53.90 /

-0.14 (-0.26%)

, BMY

Bristol-Myers

$60.21 /

-0.74 (-1.21%)

, BYSI

BeyondSpring

$10.80 /

+0.18 (+1.69%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DSNKY

Daiichi Sankyo

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXAS

Exact Sciences

$132.80 /

+2.29 (+1.75%)

, FMS

Fresenius Medical

$41.52 /

+0.16 (+0.39%)

, NVS

Novartis

$91.66 /

-0.145 (-0.16%)

, NTRA

Natera

$98.70 /

+4.09 (+4.32%)

, NEO

NeoGenomics

$50.19 /

+0.68 (+1.37%)

, MYGN

Myriad Genetics

$19.70 /

+1.03 (+5.52%)

, VCYT

Veracyte

$57.15 /

+2.31 (+4.21%)

, SGEN

Seagen

$186.55 /

+5.14 (+2.83%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, PBYI

Puma Biotechnology

$10.72 /

+0.15 (+1.42%)

, PFE

Pfizer

$41.74 /

-0.11 (-0.26%)

, ONCY

Oncolytics

$2.70 /

-0.63 (-18.92%)

, GH

Guardant Health

$126.07 /

-0.55 (-0.43%)

, LLY

Eli Lilly

$160.97 /

+2.93 (+1.85%)

, MGNX

MacroGenics

$22.70 /

+0.19 (+0.84%)

, MRK

Merck

$82.99 /

-0.54 (-0.65%)

San Antonio Breast Cancer…

San Antonio Breast Cancer Symposium (SABCS), Cancer Therapy & Research Center (CTRC) and the American Association for Cancer Research (AACR) co-host the San Antonio Breast Cancer Virtual Symposium on December 8-11. Webcast Link

ShowHide Related Items >><<
VCYT Veracyte
$57.15 /

+2.31 (+4.21%)

SGEN Seagen
$186.55 /

+5.14 (+2.83%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$41.74 /

-0.11 (-0.26%)

PBYI Puma Biotechnology
$10.72 /

+0.15 (+1.42%)

ONCY Oncolytics
$2.70 /

-0.63 (-18.92%)

NVS Novartis
$91.66 /

-0.145 (-0.16%)

NTRA Natera
$98.70 /

+4.09 (+4.32%)

NEO NeoGenomics
$50.19 /

+0.68 (+1.37%)

MYGN Myriad Genetics
$19.70 /

+1.03 (+5.52%)

MRK Merck
$82.99 /

-0.54 (-0.65%)

MGNX MacroGenics
$22.70 /

+0.19 (+0.84%)

LLY Eli Lilly
$160.97 /

+2.93 (+1.85%)

GH Guardant Health
$126.07 /

-0.55 (-0.43%)

EXAS Exact Sciences
$132.80 /

+2.29 (+1.75%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DSNKY Daiichi Sankyo
$0.00 /

+ (+0.00%)

BYSI BeyondSpring
$10.80 /

+0.18 (+1.69%)

BMY Bristol-Myers
$60.21 /

-0.74 (-1.21%)

AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

ATNX Athenex
$11.79 /

-0.31 (-2.56%)

AMGN Amgen
$228.17 /

-1.61 (-0.70%)

A Agilent
$118.84 /

+2.285 (+1.96%)

A Agilent
$118.84 /

+2.285 (+1.96%)

12/10/20 SVB Leerink
Agilent price target raised to $130 from $120 at SVB Leerink
12/02/20 Goldman Sachs
Agilent initiated with a Buy at Goldman Sachs
11/25/20
Fly Intel: Top five analyst upgrades
11/25/20 UBS
Agilent upgraded to Buy from Neutral at UBS
AMGN Amgen
$228.17 /

-1.61 (-0.70%)

12/09/20 SVB Leerink
Amgen price target raised to $253 from $243 at SVB Leerink
12/08/20 Piper Sandler
Amgen price target raised to $280 from $270 at Piper Sandler
12/08/20 Ladenburg
Ladenburg upgrades BeiGene to Buy after product approvals, ASH data
11/23/20 Mizuho
Cytokinetics regaining omecamtiv could add $3 per share, says Mizuho
ATNX Athenex
$11.79 /

-0.31 (-2.56%)

10/26/20
Fly Intel: Top five analyst initiations
10/26/20 SVB Leerink
Athenex initiated with an Outperform at SVB Leerink
09/01/20 RBC Capital
Athenex price target raised to $33 from $31 at RBC Capital
12/13/19 RBC Capital
Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital
AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

12/07/20
Fly Intel: Top five analyst upgrades
12/07/20 Morgan Stanley
AstraZeneca upgraded to Overweight from Equal Weight at Morgan Stanley
12/01/20 Morgan Stanley
COVID mRNA vaccines seen with vast majority of U.S. market, says Morgan Stanley
11/30/20 UBS
AstraZeneca upgraded to Neutral from Sell at UBS
BMY Bristol-Myers
$60.21 /

-0.74 (-1.21%)

12/09/20 Mizuho
Pentwater seeks to replace Bristol-Myers Squibb CVR trustee, says Mizuho
11/30/20 Citi
Bristol-Myers price target raised to $77 from $73 at Citi
11/23/20 BofA
BofA upgrades Schrodinger to Buy after 'major' collaboration announcement
11/17/20 Mizuho
Bristol-Myers Squibb CVR price target lowered to $3.34 from $6.17 at Mizuho
BYSI BeyondSpring
$10.80 /

+0.18 (+1.69%)

11/24/20 H.C. Wainwright
BeyondSpring price target lowered to $43 from $46 at H.C. Wainwright
06/15/20 William Blair
BeyondSpring can 'disrupt' $6.5B neutropenia market, says William Blair
06/15/20 H.C. Wainwright
BeyondSpring price target raised to $46 from $30 at H.C. Wainwright
06/09/20 H.C. Wainwright
BeyondSpring data strengthen profile for Plinabulin, says H.C. Wainwright
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

DSNKY Daiichi Sankyo
$0.00 /

+ (+0.00%)

06/08/20 Jefferies
Jefferies downgrades Daiichi Sankyo to Hold with Enhertu seen as priced in
06/08/20 Jefferies
Daiichi Sankyo downgraded to Hold from Buy at Jefferies
ESALY Eisai
$0.00 /

+ (+0.00%)

11/05/20 Jefferies
Eisai upgraded to Buy from Hold at Jefferies
09/08/20 Jefferies
Eisai downgraded to Hold from Buy at Jefferies
EXAS Exact Sciences
$132.80 /

+2.29 (+1.75%)

10/29/20
Fly Intel: Top five analyst downgrades
10/29/20 UBS
Exact Sciences downgraded to Neutral from Buy at UBS
10/28/20
Fly Intel: Top five analyst downgrades
10/28/20 Benchmark
Exact Sciences price target raised to $145 from $110 at Benchmark
FMS Fresenius Medical
$41.52 /

+0.16 (+0.39%)

12/09/20 Morgan Stanley
Fresenius Medical price target raised to EUR 75 from EUR 74 at Morgan Stanley
11/10/20 Deutsche Bank
Fresenius Medical price target lowered to EUR 87 from EUR 97 at Deutsche Bank
11/05/20 UBS
Fresenius Medical price target lowered to EUR 94 from EUR 95 at UBS
11/04/20 Nord/LB
Fresenius Medical upgraded to Buy from Hold at Nord/LB
NVS Novartis
$91.66 /

-0.145 (-0.16%)

12/03/20 Argus
Novartis price target raised to $112 from $100 at Argus
11/25/20 UBS
Novartis price target raised to CHF 99 from CHF 98 at UBS
11/10/20 JPMorgan
Novartis price target raised to CHF 85 from CHF 82 at JPMorgan
10/26/20 JMP Securities
Kura Oncology price target raised to $33 from $22 at JMP Securities
NTRA Natera
$98.70 /

+4.09 (+4.32%)

12/02/20 BTIG
Natera price target raised to $105 from $95 at BTIG
11/06/20 JPMorgan
Natera price target raised to $90 from $75 at JPMorgan
11/06/20 Morgan Stanley
Natera price target raised to $87 from $80 at Morgan Stanley
11/06/20 Piper Sandler
Natera price target raised to $92 from $76 at Piper Sandler
NEO NeoGenomics
$50.19 /

+0.68 (+1.37%)

12/11/20 BTIG
NeoGenomics initiated with a Buy at BTIG
11/20/20 SVB Leerink
NeoGenomics price target raised to $50 from $47 at SVB Leerink
10/28/20 Needham
NeoGenomics price target raised to $46 from $39 at Needham
10/28/20 Craig-Hallum
NeoGenomics price target raised to $50 from $42 at Craig-Hallum
MYGN Myriad Genetics
$19.70 /

+1.03 (+5.52%)

11/10/20 Piper Sandler
Myriad Genetics price target raised to $18 from $14 at Piper Sandler
08/17/20 Piper Sandler
ACOG recommendation 'extremely' positive for Natera and Progenity, says Piper
06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
VCYT Veracyte
$57.15 /

+2.31 (+4.21%)

11/09/20 KeyBanc
Veracyte initiated with a Sector Weight at KeyBanc
11/04/20 BTIG
Veracyte price target raised to $42 from $38 at BTIG
09/09/20 Morgan Stanley
Veracyte initiated with an Underweight at Morgan Stanley
07/31/20 Lake Street
Veracyte price target raised to $40 from $35 at Lake Street
SGEN Seagen
$186.55 /

+5.14 (+2.83%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
09/22/20 Stifel
Seattle Genetics price target raised to $165 from $145 at Stifel
09/22/20 JMP Securities
Seattle Genetics price target raised to $200 from $185 at JMP Securities
09/21/20 Piper Sandler
Tisotumab data sets Seattle Genetics up for another approval, says Piper Sandler
RHHBY Roche
$0.00 /

+ (+0.00%)

12/08/20 Roth Capital
Turning Point Therapeutics price target raised to $140 from $133 at Roth Capital
11/27/20 UBS
Roche price target lowered to CHF 365 from CHF 370 at UBS
11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
PBYI Puma Biotechnology
$10.72 /

+0.15 (+1.42%)

06/25/20 BofA
Puma Biotechnology reinstated with an Underperform at BofA
06/25/20 BofA
Puma Biotechnology initiated with an Underperform at BofA
05/20/20 Cantor Fitzgerald
Puma Biotechnology price target raised to $16 from $14 at Cantor Fitzgerald
PFE Pfizer
$41.74 /

-0.11 (-0.26%)

12/08/20 Goldman Sachs
Goldman says FDA briefing documents supportive of approval for Pfizer vaccine
12/07/20 Credit Suisse
Inter Pipeline downgraded to Underperform at Credit Suisse
12/04/20 Barclays
Pfizer price target raised to $37 from $35 at Barclays
ONCY Oncolytics
$2.70 /

-0.63 (-18.92%)

05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
01/02/20 Roth Capital
Oncolytics price target raised to $9 from $6.80 at Roth Capital
GH Guardant Health
$126.07 /

-0.55 (-0.43%)

11/06/20 JPMorgan
Guardant Health price target raised to $135 from $120 at JPMorgan
09/09/20 Morgan Stanley
Guardant Health initiated with an Overweight at Morgan Stanley
08/10/20 Canaccord
Guardion Health Sciences FDA approval landmark event, says Canaccord
06/12/20
Fly Intel: Top five analyst initiations
LLY Eli Lilly
$160.97 /

+2.93 (+1.85%)

12/10/20 Wolfe Research
Eli Lilly upgraded to Outperform from Peer Perform at Wolfe Research
12/10/20 Wolfe Research
Eli Lilly upgraded to Outperform from Peer Perform at Wolfe Research
12/04/20 JPMorgan
Eli Lilly best positioned growth story in space, says JPMorgan
12/02/20 Stifel
Blueprint Medicines initiated with a Hold at Stifel
MGNX MacroGenics
$22.70 /

+0.19 (+0.84%)

08/03/20 Citi
MacroGenics downgraded to Neutral from Buy at Citi
06/02/20 Citi
MacroGenics price target raised to $25 from $15 at Citi
06/01/20 Guggenheim
Guggenheim upgrades MacroGenics to Buy on pipeline prospects
06/01/20 Guggenheim
MacroGenics upgraded to Buy from Neutral at Guggenheim
MRK Merck
$82.99 /

-0.54 (-0.65%)

12/10/20 Piper Sandler
Piper says NGM Biopharmaceuticals R&D day highlights 'undervaluation' of shares
11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
VCYT Veracyte
$57.15 /

+2.31 (+4.21%)

SGEN Seagen
$186.55 /

+5.14 (+2.83%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$41.74 /

-0.11 (-0.26%)

PBYI Puma Biotechnology
$10.72 /

+0.15 (+1.42%)

NVS Novartis
$91.66 /

-0.145 (-0.16%)

NTRA Natera
$98.70 /

+4.09 (+4.32%)

NEO NeoGenomics
$50.19 /

+0.68 (+1.37%)

MYGN Myriad Genetics
$19.70 /

+1.03 (+5.52%)

MRK Merck
$82.99 /

-0.54 (-0.65%)

MGNX MacroGenics
$22.70 /

+0.19 (+0.84%)

LLY Eli Lilly
$160.97 /

+2.93 (+1.85%)

GH Guardant Health
$126.07 /

-0.55 (-0.43%)

EXAS Exact Sciences
$132.80 /

+2.29 (+1.75%)

BYSI BeyondSpring
$10.80 /

+0.18 (+1.69%)

BMY Bristol-Myers
$60.21 /

-0.74 (-1.21%)

AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

ATNX Athenex
$11.79 /

-0.31 (-2.56%)

AMGN Amgen
$228.17 /

-1.61 (-0.70%)

A Agilent
$118.84 /

+2.285 (+1.96%)

  • 19
    Nov
  • 07
    Oct
  • 11
    Sep
  • 10
    Sep
  • 05
    Aug
  • 19
    Jun
  • 02
    Jun
  • 30
    Apr
RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$41.74 /

-0.11 (-0.26%)

NVS Novartis
$91.66 /

-0.145 (-0.16%)

MRK Merck
$82.99 /

-0.54 (-0.65%)

LLY Eli Lilly
$160.97 /

+2.93 (+1.85%)

BMY Bristol-Myers
$60.21 /

-0.74 (-1.21%)

AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

AMGN Amgen
$228.17 /

-1.61 (-0.70%)

VCYT Veracyte
$57.15 /

+2.31 (+4.21%)

SGEN Seagen
$186.55 /

+5.14 (+2.83%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$41.74 /

-0.11 (-0.26%)

NVS Novartis
$91.66 /

-0.145 (-0.16%)

NTRA Natera
$98.70 /

+4.09 (+4.32%)

MRK Merck
$82.99 /

-0.54 (-0.65%)

LLY Eli Lilly
$160.97 /

+2.93 (+1.85%)

GH Guardant Health
$126.07 /

-0.55 (-0.43%)

EXAS Exact Sciences
$132.80 /

+2.29 (+1.75%)

ESALY Eisai
$0.00 /

+ (+0.00%)

BYSI BeyondSpring
$10.80 /

+0.18 (+1.69%)

BMY Bristol-Myers
$60.21 /

-0.74 (-1.21%)

AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

ATNX Athenex
$11.79 /

-0.31 (-2.56%)

AMGN Amgen
$228.17 /

-1.61 (-0.70%)

A Agilent
$118.84 /

+2.285 (+1.96%)

PFE Pfizer
$41.74 /

-0.11 (-0.26%)

MRK Merck
$82.99 /

-0.54 (-0.65%)

LLY Eli Lilly
$160.97 /

+2.93 (+1.85%)

EXAS Exact Sciences
$132.80 /

+2.29 (+1.75%)

BMY Bristol-Myers
$60.21 /

-0.74 (-1.21%)

AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

AMGN Amgen
$228.17 /

-1.61 (-0.70%)

A Agilent
$118.84 /

+2.285 (+1.96%)

Conference/Events
SABC / CTRC / AACR to co-host San Antonio Breast Cancer Virtual Symposium » 04:55
12/10/20
12/10
04:55
12/10/20
04:55
A

Agilent

$116.56 /

-0.57 (-0.49%)

, AMGN

Amgen

$229.78 /

+0.72 (+0.31%)

, ATNX

Athenex

$12.10 /

-0.43 (-3.43%)

, AZN

AstraZeneca

$54.04 /

-0.7 (-1.28%)

, BMY

Bristol-Myers

$60.90 /

-0.22 (-0.36%)

, BYSI

BeyondSpring

$10.61 /

+0.03 (+0.28%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DSNKY

Daiichi Sankyo

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXAS

Exact Sciences

$130.52 /

-3.02 (-2.26%)

, FMS

Fresenius Medical

$41.36 /

-0.19 (-0.46%)

, NVS

Novartis

$91.65 /

+0.385 (+0.42%)

, NTRA

Natera

$94.61 /

+1.94 (+2.09%)

, NEO

NeoGenomics

$49.51 /

+1.06 (+2.19%)

, MYGN

Myriad Genetics

$18.67 /

+0.17 (+0.92%)

, VCYT

Veracyte

$54.84 /

-5.49 (-9.10%)

, SGEN

Seagen

$181.37 /

-3.13 (-1.70%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, PBYI

Puma Biotechnology

$10.56 /

-0.82 (-7.21%)

, PFE

Pfizer

$41.85 /

-0.7 (-1.65%)

, ONCY

Oncolytics

$3.33 /

-0.48 (-12.60%)

, GH

Guardant Health

$126.62 /

+0.32 (+0.25%)

, LLY

Eli Lilly

$158.08 /

+8.895 (+5.96%)

, MGNX

MacroGenics

$22.51 /

-0.83 (-3.56%)

, MRK

Merck

$83.53 /

+0.33 (+0.40%)

San Antonio Breast Cancer…

San Antonio Breast Cancer Symposium (SABCS), Cancer Therapy & Research Center (CTRC) and the American Association for Cancer Research (AACR) co-host the San Antonio Breast Cancer Virtual Symposium on December 8-11. Webcast Link

ShowHide Related Items >><<
VCYT Veracyte
$54.84 /

-5.49 (-9.10%)

SGEN Seagen
$181.37 /

-3.13 (-1.70%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$41.85 /

-0.7 (-1.65%)

PBYI Puma Biotechnology
$10.56 /

-0.82 (-7.21%)

ONCY Oncolytics
$3.33 /

-0.48 (-12.60%)

NVS Novartis
$91.65 /

+0.385 (+0.42%)

NTRA Natera
$94.61 /

+1.94 (+2.09%)

NEO NeoGenomics
$49.51 /

+1.06 (+2.19%)

MYGN Myriad Genetics
$18.67 /

+0.17 (+0.92%)

MRK Merck
$83.53 /

+0.33 (+0.40%)

MGNX MacroGenics
$22.51 /

-0.83 (-3.56%)

LLY Eli Lilly
$158.08 /

+8.895 (+5.96%)

GH Guardant Health
$126.62 /

+0.32 (+0.25%)

EXAS Exact Sciences
$130.52 /

-3.02 (-2.26%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DSNKY Daiichi Sankyo
$0.00 /

+ (+0.00%)

BYSI BeyondSpring
$10.61 /

+0.03 (+0.28%)

BMY Bristol-Myers
$60.90 /

-0.22 (-0.36%)

AZN AstraZeneca
$54.04 /

-0.7 (-1.28%)

ATNX Athenex
$12.10 /

-0.43 (-3.43%)

AMGN Amgen
$229.78 /

+0.72 (+0.31%)

A Agilent
$116.56 /

-0.57 (-0.49%)

A Agilent
$116.56 /

-0.57 (-0.49%)

12/02/20 Goldman Sachs
Agilent initiated with a Buy at Goldman Sachs
11/25/20
Fly Intel: Top five analyst upgrades
11/25/20 UBS
Agilent upgraded to Buy from Neutral at UBS
11/24/20 SVB Leerink
Agilent price target raised to $120 from $100 at SVB Leerink
AMGN Amgen
$229.78 /

+0.72 (+0.31%)

12/09/20 SVB Leerink
Amgen price target raised to $253 from $243 at SVB Leerink
12/08/20 Piper Sandler
Amgen price target raised to $280 from $270 at Piper Sandler
12/08/20 Ladenburg
Ladenburg upgrades BeiGene to Buy after product approvals, ASH data
11/23/20 Mizuho
Cytokinetics regaining omecamtiv could add $3 per share, says Mizuho
ATNX Athenex
$12.10 /

-0.43 (-3.43%)

10/26/20
Fly Intel: Top five analyst initiations
10/26/20 SVB Leerink
Athenex initiated with an Outperform at SVB Leerink
09/01/20 RBC Capital
Athenex price target raised to $33 from $31 at RBC Capital
12/13/19 RBC Capital
Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital
AZN AstraZeneca
$54.04 /

-0.7 (-1.28%)

12/07/20
Fly Intel: Top five analyst upgrades
12/07/20 Morgan Stanley
AstraZeneca upgraded to Overweight from Equal Weight at Morgan Stanley
12/01/20 Morgan Stanley
COVID mRNA vaccines seen with vast majority of U.S. market, says Morgan Stanley
11/30/20 UBS
AstraZeneca upgraded to Neutral from Sell at UBS
BMY Bristol-Myers
$60.90 /

-0.22 (-0.36%)

12/09/20 Mizuho
Pentwater seeks to replace Bristol-Myers Squibb CVR trustee, says Mizuho
11/30/20 Citi
Bristol-Myers price target raised to $77 from $73 at Citi
11/23/20 BofA
BofA upgrades Schrodinger to Buy after 'major' collaboration announcement
11/17/20 Mizuho
Bristol-Myers Squibb CVR price target lowered to $3.34 from $6.17 at Mizuho
BYSI BeyondSpring
$10.61 /

+0.03 (+0.28%)

11/24/20 H.C. Wainwright
BeyondSpring price target lowered to $43 from $46 at H.C. Wainwright
06/15/20 William Blair
BeyondSpring can 'disrupt' $6.5B neutropenia market, says William Blair
06/15/20 H.C. Wainwright
BeyondSpring price target raised to $46 from $30 at H.C. Wainwright
06/09/20 H.C. Wainwright
BeyondSpring data strengthen profile for Plinabulin, says H.C. Wainwright
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

DSNKY Daiichi Sankyo
$0.00 /

+ (+0.00%)

06/08/20 Jefferies
Jefferies downgrades Daiichi Sankyo to Hold with Enhertu seen as priced in
06/08/20 Jefferies
Daiichi Sankyo downgraded to Hold from Buy at Jefferies
ESALY Eisai
$0.00 /

+ (+0.00%)

11/05/20 Jefferies
Eisai upgraded to Buy from Hold at Jefferies
09/08/20 Jefferies
Eisai downgraded to Hold from Buy at Jefferies
EXAS Exact Sciences
$130.52 /

-3.02 (-2.26%)

10/29/20
Fly Intel: Top five analyst downgrades
10/29/20 UBS
Exact Sciences downgraded to Neutral from Buy at UBS
10/28/20
Fly Intel: Top five analyst downgrades
10/28/20 Benchmark
Exact Sciences price target raised to $145 from $110 at Benchmark
FMS Fresenius Medical
$41.36 /

-0.19 (-0.46%)

12/09/20 Morgan Stanley
Fresenius Medical price target raised to EUR 75 from EUR 74 at Morgan Stanley
11/10/20 Deutsche Bank
Fresenius Medical price target lowered to EUR 87 from EUR 97 at Deutsche Bank
11/05/20 UBS
Fresenius Medical price target lowered to EUR 94 from EUR 95 at UBS
11/04/20 Nord/LB
Fresenius Medical upgraded to Buy from Hold at Nord/LB
NVS Novartis
$91.65 /

+0.385 (+0.42%)

12/03/20 Argus
Novartis price target raised to $112 from $100 at Argus
11/25/20 UBS
Novartis price target raised to CHF 99 from CHF 98 at UBS
11/10/20 JPMorgan
Novartis price target raised to CHF 85 from CHF 82 at JPMorgan
10/26/20 JMP Securities
Kura Oncology price target raised to $33 from $22 at JMP Securities
NTRA Natera
$94.61 /

+1.94 (+2.09%)

12/02/20 BTIG
Natera price target raised to $105 from $95 at BTIG
11/06/20 JPMorgan
Natera price target raised to $90 from $75 at JPMorgan
11/06/20 Morgan Stanley
Natera price target raised to $87 from $80 at Morgan Stanley
11/06/20 Piper Sandler
Natera price target raised to $92 from $76 at Piper Sandler
NEO NeoGenomics
$49.51 /

+1.06 (+2.19%)

11/20/20 SVB Leerink
NeoGenomics price target raised to $50 from $47 at SVB Leerink
10/28/20 Needham
NeoGenomics price target raised to $46 from $39 at Needham
10/28/20 Craig-Hallum
NeoGenomics price target raised to $50 from $42 at Craig-Hallum
09/09/20 Morgan Stanley
NeoGenomics initiated with an Overweight at Morgan Stanley
MYGN Myriad Genetics
$18.67 /

+0.17 (+0.92%)

11/10/20 Piper Sandler
Myriad Genetics price target raised to $18 from $14 at Piper Sandler
08/17/20 Piper Sandler
ACOG recommendation 'extremely' positive for Natera and Progenity, says Piper
06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
VCYT Veracyte
$54.84 /

-5.49 (-9.10%)

11/09/20 KeyBanc
Veracyte initiated with a Sector Weight at KeyBanc
11/04/20 BTIG
Veracyte price target raised to $42 from $38 at BTIG
09/09/20 Morgan Stanley
Veracyte initiated with an Underweight at Morgan Stanley
07/31/20 Lake Street
Veracyte price target raised to $40 from $35 at Lake Street
SGEN Seagen
$181.37 /

-3.13 (-1.70%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
09/22/20 Stifel
Seattle Genetics price target raised to $165 from $145 at Stifel
09/22/20 JMP Securities
Seattle Genetics price target raised to $200 from $185 at JMP Securities
09/21/20 Piper Sandler
Tisotumab data sets Seattle Genetics up for another approval, says Piper Sandler
RHHBY Roche
$0.00 /

+ (+0.00%)

12/08/20 Roth Capital
Turning Point Therapeutics price target raised to $140 from $133 at Roth Capital
11/27/20 UBS
Roche price target lowered to CHF 365 from CHF 370 at UBS
11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
PBYI Puma Biotechnology
$10.56 /

-0.82 (-7.21%)

06/25/20 BofA
Puma Biotechnology reinstated with an Underperform at BofA
06/25/20 BofA
Puma Biotechnology initiated with an Underperform at BofA
05/20/20 Cantor Fitzgerald
Puma Biotechnology price target raised to $16 from $14 at Cantor Fitzgerald
PFE Pfizer
$41.85 /

-0.7 (-1.65%)

12/08/20 Goldman Sachs
Goldman says FDA briefing documents supportive of approval for Pfizer vaccine
12/07/20 Credit Suisse
Inter Pipeline downgraded to Underperform at Credit Suisse
12/04/20 Barclays
Pfizer price target raised to $37 from $35 at Barclays
ONCY Oncolytics
$3.33 /

-0.48 (-12.60%)

05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
01/02/20 Roth Capital
Oncolytics price target raised to $9 from $6.80 at Roth Capital
GH Guardant Health
$126.62 /

+0.32 (+0.25%)

11/06/20 JPMorgan
Guardant Health price target raised to $135 from $120 at JPMorgan
09/09/20 Morgan Stanley
Guardant Health initiated with an Overweight at Morgan Stanley
08/10/20 Canaccord
Guardion Health Sciences FDA approval landmark event, says Canaccord
06/12/20
Fly Intel: Top five analyst initiations
LLY Eli Lilly
$158.08 /

+8.895 (+5.96%)

12/04/20 JPMorgan
Eli Lilly best positioned growth story in space, says JPMorgan
12/02/20 Stifel
Blueprint Medicines initiated with a Hold at Stifel
11/20/20 Stifel
Precision BioSciences price target raised to $22 from $21 at Stifel
11/17/20 Mizuho
Eli Lilly price target lowered to $156 from $164 at Mizuho
MGNX MacroGenics
$22.51 /

-0.83 (-3.56%)

08/03/20 Citi
MacroGenics downgraded to Neutral from Buy at Citi
06/02/20 Citi
MacroGenics price target raised to $25 from $15 at Citi
06/01/20 Guggenheim
Guggenheim upgrades MacroGenics to Buy on pipeline prospects
06/01/20 Guggenheim
MacroGenics upgraded to Buy from Neutral at Guggenheim
MRK Merck
$83.53 /

+0.33 (+0.40%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
VCYT Veracyte
$54.84 /

-5.49 (-9.10%)

SGEN Seagen
$181.37 /

-3.13 (-1.70%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$41.85 /

-0.7 (-1.65%)

PBYI Puma Biotechnology
$10.56 /

-0.82 (-7.21%)

NVS Novartis
$91.65 /

+0.385 (+0.42%)

NTRA Natera
$94.61 /

+1.94 (+2.09%)

NEO NeoGenomics
$49.51 /

+1.06 (+2.19%)

MYGN Myriad Genetics
$18.67 /

+0.17 (+0.92%)

MRK Merck
$83.53 /

+0.33 (+0.40%)

MGNX MacroGenics
$22.51 /

-0.83 (-3.56%)

LLY Eli Lilly
$158.08 /

+8.895 (+5.96%)

GH Guardant Health
$126.62 /

+0.32 (+0.25%)

EXAS Exact Sciences
$130.52 /

-3.02 (-2.26%)

BYSI BeyondSpring
$10.61 /

+0.03 (+0.28%)

BMY Bristol-Myers
$60.90 /

-0.22 (-0.36%)

AZN AstraZeneca
$54.04 /

-0.7 (-1.28%)

ATNX Athenex
$12.10 /

-0.43 (-3.43%)

AMGN Amgen
$229.78 /

+0.72 (+0.31%)

A Agilent
$116.56 /

-0.57 (-0.49%)

  • 19
    Nov
  • 07
    Oct
  • 11
    Sep
  • 10
    Sep
  • 05
    Aug
  • 19
    Jun
  • 02
    Jun
  • 30
    Apr
RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$41.85 /

-0.7 (-1.65%)

NVS Novartis
$91.65 /

+0.385 (+0.42%)

MRK Merck
$83.53 /

+0.33 (+0.40%)

LLY Eli Lilly
$158.08 /

+8.895 (+5.96%)

BMY Bristol-Myers
$60.90 /

-0.22 (-0.36%)

AZN AstraZeneca
$54.04 /

-0.7 (-1.28%)

AMGN Amgen
$229.78 /

+0.72 (+0.31%)

VCYT Veracyte
$54.84 /

-5.49 (-9.10%)

SGEN Seagen
$181.37 /

-3.13 (-1.70%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$41.85 /

-0.7 (-1.65%)

NVS Novartis
$91.65 /

+0.385 (+0.42%)

NTRA Natera
$94.61 /

+1.94 (+2.09%)

MRK Merck
$83.53 /

+0.33 (+0.40%)

LLY Eli Lilly
$158.08 /

+8.895 (+5.96%)

GH Guardant Health
$126.62 /

+0.32 (+0.25%)

EXAS Exact Sciences
$130.52 /

-3.02 (-2.26%)

ESALY Eisai
$0.00 /

+ (+0.00%)

BYSI BeyondSpring
$10.61 /

+0.03 (+0.28%)

BMY Bristol-Myers
$60.90 /

-0.22 (-0.36%)

AZN AstraZeneca
$54.04 /

-0.7 (-1.28%)

ATNX Athenex
$12.10 /

-0.43 (-3.43%)

AMGN Amgen
$229.78 /

+0.72 (+0.31%)

A Agilent
$116.56 /

-0.57 (-0.49%)

PFE Pfizer
$41.85 /

-0.7 (-1.65%)

MRK Merck
$83.53 /

+0.33 (+0.40%)

LLY Eli Lilly
$158.08 /

+8.895 (+5.96%)

EXAS Exact Sciences
$130.52 /

-3.02 (-2.26%)

BMY Bristol-Myers
$60.90 /

-0.22 (-0.36%)

AZN AstraZeneca
$54.04 /

-0.7 (-1.28%)

AMGN Amgen
$229.78 /

+0.72 (+0.31%)

A Agilent
$116.56 /

-0.57 (-0.49%)

Conference/Events
SABC / CTRC / AACR to co-host San Antonio Breast Cancer Virtual Symposium » 10:49
12/09/20
12/09
10:49
12/09/20
10:49
A

Agilent

$115.12 /

-2.01 (-1.72%)

, AMGN

Amgen

$229.35 /

+0.29 (+0.13%)

, ATNX

Athenex

$12.28 /

-0.25 (-2.00%)

, AZN

AstraZeneca

$54.39 /

-0.35 (-0.64%)

, BMY

Bristol-Myers

$60.77 /

-0.35 (-0.57%)

, BYSI

BeyondSpring

$10.69 /

+0.11 (+1.04%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DSNKY

Daiichi Sankyo

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXAS

Exact Sciences

$131.62 /

-1.92 (-1.44%)

, FMS

Fresenius Medical

$41.36 /

-0.19 (-0.46%)

, NVS

Novartis

$91.33 /

+0.065 (+0.07%)

, NTRA

Natera

$96.34 /

+3.67 (+3.96%)

, NEO

NeoGenomics

$48.71 /

+0.26 (+0.54%)

, MYGN

Myriad Genetics

$19.03 /

+0.53 (+2.86%)

, VCYT

Veracyte

$60.68 /

+0.35 (+0.58%)

, SGEN

Seagen

$184.35 /

-0.15 (-0.08%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, PBYI

Puma Biotechnology

$11.37 /

-0.01 (-0.09%)

, PFE

Pfizer

$41.29 /

-1.26 (-2.96%)

, ONCY

Oncolytics

$3.15 /

-0.66 (-17.32%)

, GH

Guardant Health

$127.48 /

+1.18 (+0.93%)

, LLY

Eli Lilly

$155.93 /

+6.75 (+4.52%)

, MGNX

MacroGenics

$22.73 /

-0.61 (-2.61%)

, MRK

Merck

$82.64 /

-0.56 (-0.67%)

San Antonio Breast Cancer…

San Antonio Breast Cancer Symposium (SABCS), Cancer Therapy & Research Center (CTRC) and the American Association for Cancer Research (AACR) co-host the San Antonio Breast Cancer Virtual Symposium on December 8-11. Webcast Link

ShowHide Related Items >><<
VCYT Veracyte
$60.68 /

+0.35 (+0.58%)

SGEN Seagen
$184.35 /

-0.15 (-0.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$41.29 /

-1.26 (-2.96%)

PBYI Puma Biotechnology
$11.37 /

-0.01 (-0.09%)

ONCY Oncolytics
$3.15 /

-0.66 (-17.32%)

NVS Novartis
$91.33 /

+0.065 (+0.07%)

NTRA Natera
$96.34 /

+3.67 (+3.96%)

NEO NeoGenomics
$48.71 /

+0.26 (+0.54%)

MYGN Myriad Genetics
$19.03 /

+0.53 (+2.86%)

MRK Merck
$82.64 /

-0.56 (-0.67%)

MGNX MacroGenics
$22.73 /

-0.61 (-2.61%)

LLY Eli Lilly
$155.93 /

+6.75 (+4.52%)

GH Guardant Health
$127.48 /

+1.18 (+0.93%)

EXAS Exact Sciences
$131.62 /

-1.92 (-1.44%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DSNKY Daiichi Sankyo
$0.00 /

+ (+0.00%)

BYSI BeyondSpring
$10.69 /

+0.11 (+1.04%)

BMY Bristol-Myers
$60.77 /

-0.35 (-0.57%)

AZN AstraZeneca
$54.39 /

-0.35 (-0.64%)

ATNX Athenex
$12.28 /

-0.25 (-2.00%)

AMGN Amgen
$229.35 /

+0.29 (+0.13%)

A Agilent
$115.12 /

-2.01 (-1.72%)

A Agilent
$115.12 /

-2.01 (-1.72%)

12/02/20 Goldman Sachs
Agilent initiated with a Buy at Goldman Sachs
11/25/20
Fly Intel: Top five analyst upgrades
11/25/20 UBS
Agilent upgraded to Buy from Neutral at UBS
11/24/20 SVB Leerink
Agilent price target raised to $120 from $100 at SVB Leerink
AMGN Amgen
$229.35 /

+0.29 (+0.13%)

12/09/20 SVB Leerink
Amgen price target raised to $253 from $243 at SVB Leerink
12/08/20 Piper Sandler
Amgen price target raised to $280 from $270 at Piper Sandler
12/08/20 Ladenburg
Ladenburg upgrades BeiGene to Buy after product approvals, ASH data
11/23/20 Mizuho
Cytokinetics regaining omecamtiv could add $3 per share, says Mizuho
ATNX Athenex
$12.28 /

-0.25 (-2.00%)

10/26/20
Fly Intel: Top five analyst initiations
10/26/20 SVB Leerink
Athenex initiated with an Outperform at SVB Leerink
09/01/20 RBC Capital
Athenex price target raised to $33 from $31 at RBC Capital
12/13/19 RBC Capital
Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital
AZN AstraZeneca
$54.39 /

-0.35 (-0.64%)

12/07/20
Fly Intel: Top five analyst upgrades
12/07/20 Morgan Stanley
AstraZeneca upgraded to Overweight from Equal Weight at Morgan Stanley
12/01/20 Morgan Stanley
COVID mRNA vaccines seen with vast majority of U.S. market, says Morgan Stanley
11/30/20 UBS
AstraZeneca upgraded to Neutral from Sell at UBS
BMY Bristol-Myers
$60.77 /

-0.35 (-0.57%)

11/30/20 Citi
Bristol-Myers price target raised to $77 from $73 at Citi
11/23/20 BofA
BofA upgrades Schrodinger to Buy after 'major' collaboration announcement
11/17/20 Mizuho
Bristol-Myers Squibb CVR price target lowered to $3.34 from $6.17 at Mizuho
11/16/20 Societe Generale
Bristol-Myers upgraded to Buy from Hold at Societe Generale
BYSI BeyondSpring
$10.69 /

+0.11 (+1.04%)

11/24/20 H.C. Wainwright
BeyondSpring price target lowered to $43 from $46 at H.C. Wainwright
06/15/20 William Blair
BeyondSpring can 'disrupt' $6.5B neutropenia market, says William Blair
06/15/20 H.C. Wainwright
BeyondSpring price target raised to $46 from $30 at H.C. Wainwright
06/09/20 H.C. Wainwright
BeyondSpring data strengthen profile for Plinabulin, says H.C. Wainwright
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

DSNKY Daiichi Sankyo
$0.00 /

+ (+0.00%)

06/08/20 Jefferies
Jefferies downgrades Daiichi Sankyo to Hold with Enhertu seen as priced in
06/08/20 Jefferies
Daiichi Sankyo downgraded to Hold from Buy at Jefferies
ESALY Eisai
$0.00 /

+ (+0.00%)

11/05/20 Jefferies
Eisai upgraded to Buy from Hold at Jefferies
09/08/20 Jefferies
Eisai downgraded to Hold from Buy at Jefferies
EXAS Exact Sciences
$131.62 /

-1.92 (-1.44%)

10/29/20
Fly Intel: Top five analyst downgrades
10/29/20 UBS
Exact Sciences downgraded to Neutral from Buy at UBS
10/28/20
Fly Intel: Top five analyst downgrades
10/28/20 Benchmark
Exact Sciences price target raised to $145 from $110 at Benchmark
FMS Fresenius Medical
$41.36 /

-0.19 (-0.46%)

11/10/20 Deutsche Bank
Fresenius Medical price target lowered to EUR 87 from EUR 97 at Deutsche Bank
11/05/20 UBS
Fresenius Medical price target lowered to EUR 94 from EUR 95 at UBS
11/04/20 Nord/LB
Fresenius Medical upgraded to Buy from Hold at Nord/LB
10/30/20 JPMorgan
Fresenius Medical price target lowered to EUR 91.40 from EUR 94.80 at JPMorgan
NVS Novartis
$91.33 /

+0.065 (+0.07%)

12/03/20 Argus
Novartis price target raised to $112 from $100 at Argus
11/25/20 UBS
Novartis price target raised to CHF 99 from CHF 98 at UBS
11/10/20 JPMorgan
Novartis price target raised to CHF 85 from CHF 82 at JPMorgan
10/26/20 JMP Securities
Kura Oncology price target raised to $33 from $22 at JMP Securities
NTRA Natera
$96.34 /

+3.67 (+3.96%)

12/02/20 BTIG
Natera price target raised to $105 from $95 at BTIG
11/06/20 JPMorgan
Natera price target raised to $90 from $75 at JPMorgan
11/06/20 Morgan Stanley
Natera price target raised to $87 from $80 at Morgan Stanley
11/06/20 Piper Sandler
Natera price target raised to $92 from $76 at Piper Sandler
NEO NeoGenomics
$48.71 /

+0.26 (+0.54%)

11/20/20 SVB Leerink
NeoGenomics price target raised to $50 from $47 at SVB Leerink
10/28/20 Needham
NeoGenomics price target raised to $46 from $39 at Needham
10/28/20 Craig-Hallum
NeoGenomics price target raised to $50 from $42 at Craig-Hallum
09/09/20 Morgan Stanley
NeoGenomics initiated with an Overweight at Morgan Stanley
MYGN Myriad Genetics
$19.03 /

+0.53 (+2.86%)

11/10/20 Piper Sandler
Myriad Genetics price target raised to $18 from $14 at Piper Sandler
08/17/20 Piper Sandler
ACOG recommendation 'extremely' positive for Natera and Progenity, says Piper
06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
VCYT Veracyte
$60.68 /

+0.35 (+0.58%)

11/09/20 KeyBanc
Veracyte initiated with a Sector Weight at KeyBanc
11/04/20 BTIG
Veracyte price target raised to $42 from $38 at BTIG
09/09/20 Morgan Stanley
Veracyte initiated with an Underweight at Morgan Stanley
07/31/20 Lake Street
Veracyte price target raised to $40 from $35 at Lake Street
SGEN Seagen
$184.35 /

-0.15 (-0.08%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
09/22/20 Stifel
Seattle Genetics price target raised to $165 from $145 at Stifel
09/22/20 JMP Securities
Seattle Genetics price target raised to $200 from $185 at JMP Securities
09/21/20 Piper Sandler
Tisotumab data sets Seattle Genetics up for another approval, says Piper Sandler
RHHBY Roche
$0.00 /

+ (+0.00%)

12/08/20 Roth Capital
Turning Point Therapeutics price target raised to $140 from $133 at Roth Capital
11/27/20 UBS
Roche price target lowered to CHF 365 from CHF 370 at UBS
11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
PBYI Puma Biotechnology
$11.37 /

-0.01 (-0.09%)

06/25/20 BofA
Puma Biotechnology reinstated with an Underperform at BofA
06/25/20 BofA
Puma Biotechnology initiated with an Underperform at BofA
05/20/20 Cantor Fitzgerald
Puma Biotechnology price target raised to $16 from $14 at Cantor Fitzgerald
PFE Pfizer
$41.29 /

-1.26 (-2.96%)

12/08/20 Goldman Sachs
Goldman says FDA briefing documents supportive of approval for Pfizer vaccine
12/07/20 Credit Suisse
Inter Pipeline downgraded to Underperform at Credit Suisse
12/04/20 Barclays
Pfizer price target raised to $37 from $35 at Barclays
ONCY Oncolytics
$3.15 /

-0.66 (-17.32%)

05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
01/02/20 Roth Capital
Oncolytics price target raised to $9 from $6.80 at Roth Capital
GH Guardant Health
$127.48 /

+1.18 (+0.93%)

11/06/20 JPMorgan
Guardant Health price target raised to $135 from $120 at JPMorgan
09/09/20 Morgan Stanley
Guardant Health initiated with an Overweight at Morgan Stanley
08/10/20 Canaccord
Guardion Health Sciences FDA approval landmark event, says Canaccord
06/12/20
Fly Intel: Top five analyst initiations
LLY Eli Lilly
$155.93 /

+6.75 (+4.52%)

12/04/20 JPMorgan
Eli Lilly best positioned growth story in space, says JPMorgan
12/02/20 Stifel
Blueprint Medicines initiated with a Hold at Stifel
11/20/20 Stifel
Precision BioSciences price target raised to $22 from $21 at Stifel
11/17/20 Mizuho
Eli Lilly price target lowered to $156 from $164 at Mizuho
MGNX MacroGenics
$22.73 /

-0.61 (-2.61%)

08/03/20 Citi
MacroGenics downgraded to Neutral from Buy at Citi
06/02/20 Citi
MacroGenics price target raised to $25 from $15 at Citi
06/01/20 Guggenheim
Guggenheim upgrades MacroGenics to Buy on pipeline prospects
06/01/20 Guggenheim
MacroGenics upgraded to Buy from Neutral at Guggenheim
MRK Merck
$82.64 /

-0.56 (-0.67%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
VCYT Veracyte
$60.68 /

+0.35 (+0.58%)

SGEN Seagen
$184.35 /

-0.15 (-0.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$41.29 /

-1.26 (-2.96%)

PBYI Puma Biotechnology
$11.37 /

-0.01 (-0.09%)

NVS Novartis
$91.33 /

+0.065 (+0.07%)

NTRA Natera
$96.34 /

+3.67 (+3.96%)

NEO NeoGenomics
$48.71 /

+0.26 (+0.54%)

MYGN Myriad Genetics
$19.03 /

+0.53 (+2.86%)

MRK Merck
$82.64 /

-0.56 (-0.67%)

MGNX MacroGenics
$22.73 /

-0.61 (-2.61%)

LLY Eli Lilly
$155.93 /

+6.75 (+4.52%)

GH Guardant Health
$127.48 /

+1.18 (+0.93%)

EXAS Exact Sciences
$131.62 /

-1.92 (-1.44%)

BYSI BeyondSpring
$10.69 /

+0.11 (+1.04%)

BMY Bristol-Myers
$60.77 /

-0.35 (-0.57%)

AZN AstraZeneca
$54.39 /

-0.35 (-0.64%)

ATNX Athenex
$12.28 /

-0.25 (-2.00%)

AMGN Amgen
$229.35 /

+0.29 (+0.13%)

A Agilent
$115.12 /

-2.01 (-1.72%)

  • 19
    Nov
  • 07
    Oct
  • 11
    Sep
  • 10
    Sep
  • 05
    Aug
  • 19
    Jun
  • 02
    Jun
  • 30
    Apr
RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$41.29 /

-1.26 (-2.96%)

NVS Novartis
$91.33 /

+0.065 (+0.07%)

MRK Merck
$82.64 /

-0.56 (-0.67%)

LLY Eli Lilly
$155.93 /

+6.75 (+4.52%)

BMY Bristol-Myers
$60.77 /

-0.35 (-0.57%)

AZN AstraZeneca
$54.39 /

-0.35 (-0.64%)

AMGN Amgen
$229.35 /

+0.29 (+0.13%)

VCYT Veracyte
$60.68 /

+0.35 (+0.58%)

SGEN Seagen
$184.35 /

-0.15 (-0.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$41.29 /

-1.26 (-2.96%)

NVS Novartis
$91.33 /

+0.065 (+0.07%)

NTRA Natera
$96.34 /

+3.67 (+3.96%)

MRK Merck
$82.64 /

-0.56 (-0.67%)

LLY Eli Lilly
$155.93 /

+6.75 (+4.52%)

GH Guardant Health
$127.48 /

+1.18 (+0.93%)

EXAS Exact Sciences
$131.62 /

-1.92 (-1.44%)

ESALY Eisai
$0.00 /

+ (+0.00%)

BYSI BeyondSpring
$10.69 /

+0.11 (+1.04%)

BMY Bristol-Myers
$60.77 /

-0.35 (-0.57%)

AZN AstraZeneca
$54.39 /

-0.35 (-0.64%)

ATNX Athenex
$12.28 /

-0.25 (-2.00%)

AMGN Amgen
$229.35 /

+0.29 (+0.13%)

A Agilent
$115.12 /

-2.01 (-1.72%)

PFE Pfizer
$41.29 /

-1.26 (-2.96%)

MRK Merck
$82.64 /

-0.56 (-0.67%)

LLY Eli Lilly
$155.93 /

+6.75 (+4.52%)

EXAS Exact Sciences
$131.62 /

-1.92 (-1.44%)

BMY Bristol-Myers
$60.77 /

-0.35 (-0.57%)

AZN AstraZeneca
$54.39 /

-0.35 (-0.64%)

AMGN Amgen
$229.35 /

+0.29 (+0.13%)

A Agilent
$115.12 /

-2.01 (-1.72%)

Hot Stocks
Myriad Genetics expands myChoice Tumor Testing in Europe, China » 07:56
11/16/20
11/16
07:56
11/16/20
07:56
MYGN

Myriad Genetics

$16.75 /

+0.03 (+0.18%)

, AZN

AstraZeneca

$57.37 /

+0.54 (+0.95%)

, MRK

Merck

$81.10 /

+1.26 (+1.58%)

Myriad Genetics announced…

Myriad Genetics announced the expansion of Myriad myChoice tumor testing in several European markets and China. Myriad myChoice CDx is a clinically-validated genomic instability test. The test enables physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in potentially increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors, including Lynparza. A biomarker subgroup analysis of the PAOLA-1 Phase III trial of Lynparza included patients with advanced ovarian cancer and homologous recombination deficient-positive tumors as detected by the myChoice test, including those with BRCA gene mutations. The trial showed that Lynparza in combination with bevacizumab maintenance treatment improved progression-free survival to a median of 37.2 months versus 17.7 months for bevacizumab alone in patients with HRD-positive advanced ovarian cancer. Recently, the European Commission authorized use of Lynparza for the first-line maintenance treatment with bevacizumab of patients with HRD-positive advanced ovarian cancer. Lynparza is jointly developed and commercialized by AstraZeneca (AZN) and Merck (MRK). As part of the expansion in Europe, Myriad will license and provide technological support to leading pathology institutes in Germany and France. Additionally, Myriad will support European customers by performing testing out of its clinical laboratory at the company's global headquarters in Salt Lake City. Also, the institutes in Europe will perform the tests with Myriad's myChoice CDx PLUS assay. Myriad myChoice CDx PLUS is CE-marked in accordance with the In-Vitro Diagnostic Devices Directive. Another collaboration in China provides that Myriad will partner with Burning Rock Biotech, a leader in next generation sequencing technology for precision oncology, to provide myChoice for HRD testing in Phase III clinical studies and clinics throughout China. Myriad will provide Burning Rock with access to its proprietary myChoice technology. The partnership with Burning Rock expands global access to myChoice and positions the test as a preferred developmental companion diagnostic in this important drug development category.

ShowHide Related Items >><<
MYGN Myriad Genetics
$16.75 /

+0.03 (+0.18%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

MYGN Myriad Genetics
$16.75 /

+0.03 (+0.18%)

11/10/20 Piper Sandler
Myriad Genetics price target raised to $18 from $14 at Piper Sandler
08/17/20 Piper Sandler
ACOG recommendation 'extremely' positive for Natera and Progenity, says Piper
06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

11/11/20 Oppenheimer
Amgen price target raised to $280 from $275 at Oppenheimer
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
MRK Merck
$81.10 /

+1.26 (+1.58%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
MYGN Myriad Genetics
$16.75 /

+0.03 (+0.18%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

Hot Stocks
Burning Rock announces in-licensing of Myriad myChoice tumor testing in China » 20:03
11/15/20
11/15
20:03
11/15/20
20:03
BNR

Burning Rock Biotech

$28.50 /

+1.5 (+5.56%)

, MYGN

Myriad Genetics

$16.75 /

+0.03 (+0.18%)

Burning Rock Biotech…

Burning Rock Biotech (BNR) announced that it entered into a development and commercialization agreement with Myriad Genetics (MYGN) which will bring myChoice tumor testing for homologous recombination deficiency, or HRD, to China. The Myriad myChoice CDx test enables physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in potentially increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. In May 2020, the U.S. Food and Drug Administration approved myChoice CDx for use as a companion diagnostic to identify patients with advanced ovarian cancer with HRD-positive status, who are eligible or may become eligible, for first-line maintenance treatment with Lynparza in combination with bevacizumab. In August 2020, myChoice was exclusively cited and the only named commercial companion diagnostic by the American Society of Clinical Oncology in new recommendations on the use of PARP inhibitors for the treatment and management of certain patients with advanced ovarian cancer. The new recommendations, based on clinical trial results, were published in the Journal of Clinical Oncology. Through the partnership with Myriad, Burning Rock will perform myChoice HRD testing in China for collaborative drug development studies and for clinics.

ShowHide Related Items >><<
MYGN Myriad Genetics
$16.75 /

+0.03 (+0.18%)

BNR Burning Rock Biotech
$28.50 /

+1.5 (+5.56%)

BNR Burning Rock Biotech
$28.50 /

+1.5 (+5.56%)

07/07/20 Cowen
Burning Rock Biotech initiated with an Outperform at Cowen
07/07/20 Morgan Stanley
Burning Rock Biotech initiated with an Overweight at Morgan Stanley
07/07/20 Cowen
Burning Rock Biotech initiated with an Outperform at Cowen
MYGN Myriad Genetics
$16.75 /

+0.03 (+0.18%)

11/10/20 Piper Sandler
Myriad Genetics price target raised to $18 from $14 at Piper Sandler
08/17/20 Piper Sandler
ACOG recommendation 'extremely' positive for Natera and Progenity, says Piper
06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
MYGN Myriad Genetics
$16.75 /

+0.03 (+0.18%)

  • 12
    Jun
BNR Burning Rock Biotech
$28.50 /

+1.5 (+5.56%)

Hot Stocks
Myriad Genetics announces data on Vectra testing, biomarkers » 07:19
11/11/20
11/11
07:19
11/11/20
07:19
MYGN

Myriad Genetics

$17.09 /

+0.07 (+0.41%)

At the annual meeting of…

At the annual meeting of the American College of Rheumatology, Myriad Genetics shared new data further demonstrating that Vectra testing and three additional biomarkers, combined with traditional risk factors, can predict the risk of cardiovascular events in patients with rheumatoid arthritis. Also, presented at the meeting was a study showing that Vectra is a significant predictor for joint damage, and is a better predictor than several tested subjective measures. Vectra is an advanced blood test that objectively measures inflammation caused by RA. Title: External Validation of a Multi-Biomarker-Based Cardiovascular Disease Risk Prediction Score for Rheumatoid Arthritis Patients: This validation study assessed the performance of the Multi-Biomarker-Based Cardiovascular Disease Risk Prediction Score in a non-Medicare patient population. The goal of the study was to validate the risk score in a cohort with median age of 54 years that was younger than, and independent of, the Medicare cohort used for test development. The study found that the Vectra-based CVD risk score was a significant predictor of CVD risk, with hazard ratio &#61; 3.99; i.e., for every 1-unit increase in the score, the CVD event rate was ~4 times higher. Title: Performance of the MBDA-based CVD risk score in RA patient groups of clinical interest: The purpose of this study was to evaluate the ability of a risk score that combines Vectra, TNF-R1, MMP-3, leptin, age and traditional risk factors to predict 3-year risk for myocardial infarction, stroke, or fatal CVD for RA patients in subgroups of interest. The study found that, in a cohort of 10,275 Medicare patients, with high prevalence of comorbidities, such as diabetes and hypertension, the Vectra-based CVD risk prediction score had good accuracy overall and in subgroups based on level of a Vectra score, sex, and statin use. Title: Comparison of MBDA Score, Patient Global Assessment, and Evaluator Global Assessment for Predicting Risk of Radiographic Progression: In a cohort of 766 patients from one registry and two clinical trials, this study compared Vectra, patient global assessment, and evaluator global assessment in terms of their abilities to predict risk of radiographic progression. The study found Vectra significantly predicted risk for RP, with univariate OR&#61;1.53, p&#61;5.3x10-8. In contrast, neither PGA nor EGA predicted RP. Vectra predicted RP regardless of whether PGA and EGA were concordant or discordant. RA affects more than one million people in the United States. Lost productivity associated with RA is substantial, with approximately 20-70% of individuals working at the time of their RA diagnosis being disabled after seven to 10 years. RA is an inflammatory autoimmune disease that attacks a patient's joints and often affects other organ systems, contributing to increased disability, significant morbidity, increased mortality and financial burden. The risk of RP, defined as change in total Sharp score greater than5 units per year, is a function of Vectra score. Increased risk of RP means greater irreversible joint damage. Three out of four rheumatologists have used Vectra and have ordered more than one million tests for their RA patients. The ACR includes Multi-Biomarker Disease Activity Score as a disease activity measure that meets the minimum standard for regular use for patients with rheumatoid arthritis. Those recommendations were published in the journal Arthritis Care & Research.

ShowHide Related Items >><<
MYGN Myriad Genetics
$17.09 /

+0.07 (+0.41%)

MYGN Myriad Genetics
$17.09 /

+0.07 (+0.41%)

11/10/20 Piper Sandler
Myriad Genetics price target raised to $18 from $14 at Piper Sandler
08/17/20 Piper Sandler
ACOG recommendation 'extremely' positive for Natera and Progenity, says Piper
06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
MYGN Myriad Genetics
$17.09 /

+0.07 (+0.41%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.